Elite Pharmaceuticals Statistics
Total Valuation
Elite Pharmaceuticals has a market cap or net worth of 416.41 million. The enterprise value is 419.67 million.
| Market Cap | 416.41M |
| Enterprise Value | 419.67M |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Elite Pharmaceuticals has 1.07 billion shares outstanding. The number of shares has increased by 2.46% in one year.
| Shares Outstanding | 1.07B |
| Shares Change (YoY) | +2.46% |
| Shares Change (QoQ) | +4.05% |
| Owned by Insiders (%) | 22.32% |
| Owned by Institutions (%) | n/a |
| Float | 829.88M |
Valuation Ratios
The trailing PE ratio is 20.48.
| PE Ratio | 20.48 |
| Forward PE | n/a |
| PS Ratio | 6.04 |
| PB Ratio | 7.15 |
| P/FCF Ratio | 422.95 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 28.35, with an EV/FCF ratio of 426.26.
| EV / Earnings | 21.43 |
| EV / Sales | 6.32 |
| EV / EBITDA | 28.35 |
| EV / EBIT | 32.16 |
| EV / FCF | 426.26 |
Financial Position
The company has a current ratio of 3.08, with a Debt / Equity ratio of 20.02.
| Current Ratio | 3.08 |
| Quick Ratio | 2.06 |
| Debt / Equity | 20.02 |
| Debt / EBITDA | 0.79 |
| Debt / FCF | 11.85 |
| Interest Coverage | 18.13 |
Financial Efficiency
Return on equity (ROE) is 44.32% and return on invested capital (ROIC) is 15.12%.
| Return on Equity (ROE) | 44.32% |
| Return on Assets (ROA) | 12.14% |
| Return on Capital (ROIC) | 15.12% |
| Revenue Per Employee | 1.04M |
| Profits Per Employee | 305,978 |
| Employee Count | 64 |
| Asset Turnover | 0.99 |
| Inventory Turnover | 2.91 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +397.44% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +397.44% |
| 50-Day Moving Average | 0.23 |
| 200-Day Moving Average | 0.17 |
| Relative Strength Index (RSI) | 74.44 |
| Average Volume (20 Days) | 3,602,609 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.09 |
Income Statement
In the last 12 months, Elite Pharmaceuticals had revenue of 66.45 million and earned 19.58 million in profits. Earnings per share was 0.02.
| Revenue | 66.45M |
| Gross Profit | 30.08M |
| Operating Income | 13.05M |
| Pretax Income | 14,083 |
| Net Income | 19.58M |
| EBITDA | 14.47M |
| EBIT | 13.05M |
| Earnings Per Share (EPS) | 0.02 |
Balance Sheet
The company has 8.41 million in cash and 11.66 million in debt, giving a net cash position of -3.26 million or -0.00 per share.
| Cash & Cash Equivalents | 8.41M |
| Total Debt | 11.66M |
| Net Cash | -3.26M |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | 58.25M |
| Book Value Per Share | 0.05 |
| Working Capital | 29.15M |
Cash Flow
In the last 12 months, operating cash flow was 2.57 million and capital expenditures -1.59 million, giving a free cash flow of 984,540.
| Operating Cash Flow | 2.57M |
| Capital Expenditures | -1.59M |
| Free Cash Flow | 984,540 |
| FCF Per Share | 0.00 |
Margins
Gross margin is 45.27%, with operating and profit margins of 19.64% and 29.47%.
| Gross Margin | 45.27% |
| Operating Margin | 19.64% |
| Pretax Margin | 0.02% |
| Profit Margin | 29.47% |
| EBITDA Margin | 21.77% |
| EBIT Margin | 19.64% |
| FCF Margin | 1.48% |
Dividends & Yields
Elite Pharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.46% |
| Shareholder Yield | -2.46% |
| Earnings Yield | 4.88% |
| FCF Yield | 0.24% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |